Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Bupropion + duloxetine is a combination of two antidepressant medications, each with distinct mechanisms of action. Bupropion is a norepinephrine-dopamine reuptake inhibitor (NDRI), while duloxetine is a serotonin-norepinephrine reuptake inhibitor (SNRI). This combination has been studied for use in treatment-resistant major depressive disorder, where monotherapy with either agent was insufficient. The rationale for combining these drugs lies in their complementary pharmacological profiles, potentially offering broader neurotransmitter modulation and improved efficacy in certain patients. However, the combination carries an increased risk of adverse effects and drug interactions, including the potential for serotonin syndrome and elevated blood pressure[2][1][3]. Use should be closely monitored by healthcare professionals.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on bupropion + duloxetine.